Intestinal Inflammations
We recommend
Impact of Tofacitinib on the Quality of Life of Patients with Ulcerative Colitis
Tofacitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of certain rheumatic diseases and ulcerative colitis (UC). The work presented at this year's 18th congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen, Denmark, focused on its impact on the quality of life in terms of physical and mental functions in patients with UC.
Safety of Tofacitinib in Ulcerative Colitis – Combined Results of 6 Studies
At the annual meeting of the American Gastroenterological Association (ACG) in October 2023 in…
Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?
The oral Janus kinase inhibitor (JAKi) tofacitinib is currently approved for the treatment of…
Articles on this topic
Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world…
Tofacitinib Through the Eyes of Patients: Rapid Response After Treatment Initiation
How does tofacitinib fare in the treatment of ulcerative colitis in real clinical practice…
Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice in the USA
A recently published study summarizes the characteristics of patients newly treated with…
Presence of Risk Factors Associated with Colectomy in Patients with Ulcerative Colitis in Studies with Tofacitinib
One of the important goals of active ulcerative colitis therapy is the prevention of…
Effectiveness of Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Clinical Practice
One of the new modalities for the treatment of ulcerative colitis (UC) is tofacitinib. Its…
Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations
Authors of a freshly published study based on real-world data from the USA investigated…
Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure
Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are…
Tofacitinib Helps Restore Intestinal Epithelial Barrier
The Janus kinase inhibitor (JAKi) tofacitinib was relatively recently approved for the…
Maintenance of Remission with Tofacitinib in Patients with UC – Results of the OCTAVE Open Study
Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations
- Effectiveness of Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Clinical Practice
- Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure
- Tofacitinib Helps Restore Intestinal Epithelial Barrier
- Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?
- Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
Journal on this topic
Related topic
Interesting links